newsfilter
← Earnings
Earnings Releases·

Amylyx Pharmaceuticals — Third Quarter 2026 Earnings Summary

Amylyx Pharmaceuticals reported positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia, demonstrating a 55% reduction in severe hypoglycemic events compared to placebo. The company completed an upsized public offering that generated approximately $545 million in net proceeds, strengthening its balance sheet to support a potential 2027 launch of avexitide if approved. Amylyx remains on track to submit a New Drug Application to the FDA by the end of 2026 and plans to present the LUCIDITY trial data as a late-breaking oral presentation at ObesityWeek 2026.

Company
AMYLYX PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology